.

Pharmaceutical Business Intelligence

  • Find generic sources and suppliers
  • Formulary management
  • Drug patents and clinical trials in dozens of countries

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 6,770,660

« Back to Dashboard

Which drugs does patent 6,770,660 protect, and when does it expire?

Patent 6,770,660 protects AGGRASTAT and is included in two NDAs.

This patent has five patent family members in five countries.

Summary for Patent: 6,770,660

Title: Method for inhibiting platelet aggregation
Abstract:A method for inhibiting platelet aggregation in a patient in need thereof, comprising 1) administering to the patient a bolus injection of an active drug, in an amount of about 25 .mu.g/kg, and 2) administering to the patient, after the bolus injection, an intravenous infusion for a period of between about 12 hours and about 72 hours, of the active drug, in an amount of about 0.15 .mu.g/kg/min, wherein the active drug is tirofiban or a salt thereof.
Inventor(s): DiBattiste; Peter M. (Chalfont, PA), Schneider; David (Shelburne, VT)
Assignee: Artery LLC (Baltimore, MA)
Application Number:10/427,436
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Medicure
AGGRASTAT
tirofiban hydrochloride
INJECTABLE;INJECTION020912-001May 14, 1998DISCNNoNo6,770,660► Subscribe A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS
Medicure
AGGRASTAT
tirofiban hydrochloride
SOLUTION;INJECTION020912-002Aug 31, 2016RXYesYes6,770,660► Subscribe A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS
Medicure
AGGRASTAT
tirofiban hydrochloride
INJECTABLE;INJECTION020913-002May 17, 2002RXYesNo6,770,660► Subscribe A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS
Medicure
AGGRASTAT
tirofiban hydrochloride
INJECTABLE;INJECTION020913-003Apr 20, 2000RXYesYes6,770,660► Subscribe A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS
Medicure
AGGRASTAT
tirofiban hydrochloride
INJECTABLE;INJECTION020913-001May 14, 1998DISCNNoNo6,770,660► Subscribe A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,770,660

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2003234596► Subscribe
Canada2483929► Subscribe
European Patent Office1503753► Subscribe
Japan2005532306► Subscribe
World Intellectual Property Organization (WIPO)03092767► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc